Moderna to expand mRNA vaccines commercial footprint In Europe

Coronavirus vaccine developer Moderna (Nasdaq: MRNA), which is pioneering messenger RNA (mRNA) therapeutics and vaccines, aims to expand its commercial network across six additional countries in Europe.

Moderna plans to establish a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland, and Sweden to support the delivery of mRNA vaccines and therapeutics locally. This follows the recent announcement of plans for four new subsidiaries in Malaysia, Taiwan, Singapore, and Hong Kong.

“Europe has played a critical role in Moderna’s ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve,” said Stéphane Bancel, chief executive of Moderna, adding: “I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe.”